ニュージャージー州ラーウェイ - メルク・アンド・カンパニー（NYSE:MRK）は本日、米国食品医薬品局（FDA）がモノクローナル抗体薬「ENFLONSIA™（エンフロンシア、一般名：clesrovimab-cfor）」を新生児および乳児の最初のRSVシーズンにおける呼吸器合胞体 ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

これは米国食品医薬品局（FDA）がメルク・アンド・カンパニーの呼吸器合胞体ウイルス（RSV）ワクチン「Enflonsia（clesrovimab）」を承認したことを受けたものである。このワクチンはSobiに多額のロイヤリティをもたらす製品「Beyfortus」と競合することになる。

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in US infants.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Merck scored a major win with FDA approval for Enflonsia, its fresh RSV-fighting antibody aimed at shielding infants. This ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.